The fourth session of the FDA Town Hall Meeting at the Transcatheter Cardiovascular Therapeutics (TCT) conference was titled Regulation and Reimbursement: Global Imperatives and Trends. It began with the keynote address, The Intersection of Innovation, Payment and Regulatory Approval in the Future of Interventional Cardiology, delivered by Jack L. Lewin, MD, CEO of the Cardiovascular Research Foundation. He discussed 5 critical trends affecting innovation: progression of science, information technology and big data, changing politics and public scrutiny of healthcare quality and costs, regulatory expansion, and healthcare payment reform.
The fourth session of the FDA Town Hall Meeting at the Transcatheter Cardiovascular Therapeutics (TCT) conference was titled “Regulation and Reimbursement: Global Imperatives and Trends.” It began with the keynote address, “The Intersection of Innovation, Payment and Regulatory Approval in the Future of Interventional Cardiology,” delivered by Jack L. Lewin, MD, CEO of the Cardiovascular Research Foundation. He discussed 5 critical trends affecting innovation: progression of science, information technology and big data, changing politics and public scrutiny of healthcare quality and costs, regulatory expansion, and healthcare payment reform. According to Dr Lewin, getting involved in payment reform is critical during this transition of payment models toward value-based models. He stated that adaptation is necessary as changes take place. He concluded with predictions, including the following: big data impacts will be huge, regulators will be more empowered with more data, products will come to market more quickly, regulatory strategies will change, and the United States will not see a decline in innovation.
Next, Alan G. Fraser, MD, professor at the Cardiff University School of Medicine in the United Kingdom, presented “Status Update on European Medical Device Regulatory Reform Initiatives.” He referred the audience to a paper from the European Society of Cardiology published 2 years ago which details a review of the current regulatory system in Europe and some suggestions for reform. According to Dr Fraser, new legislation, involving over 700 amendments, has recently moved through the European Parliament regarding medical devices. A decision was made last week, but a public statement has not been made. Most changes are aimed at increasing transparency, efficacy, and patient safety. Dr Fraser concluded by calling for greater international collaboration.
The final presentation of the session, “Enlightened Perspectives from NICE,” was presented by Amanda I. Adler, chair of the Technology Appraisals Committee at the National Institute for Health and Care Excellence (NICE) in Cambridge, United Kingdom. According to Ms Adler, any new technology in the United Kingdom must go through regulators first, followed by NICE, which then determines if the National Health System should adopt it. NICE uses the quality-adjusted life-year (QALY) as a measure of health effectiveness, and it heavily weighs the cost and value of a new technology. Ms Adler also stated that NICE makes an effort to be timely, transparent, and up-to-date. Lastly, she reviewed CV devices that have been considered in the past 2 years.
Following the presentations, there was a brief discussion regarding regulation and reimbursement in countries outside the United States. Takeshi Kimura, MD, of the Kyoto University Hospital in Sakyo-ku, Japan; Dr Ashkoth Seth from Fortis Escorts Heart Institute in New Delhi, India; and Ross Prpic, MD, of the Pacific Clinical Research Group in North Sydney, Australia, were asked: “How does the cost of a device affect its access at the bedside in your country?” In Japan, there is a public insurance system, so essentially, there is no effect. When a device is approved, reimbursement is guaranteed. In India, device cost and approval cost are not related. In Australia, the approval process is separate from reimbursement.
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
A Focus on Women: AUA Best Posters Highlight Female Athletes, Prenatal Care, and Women in Urology
May 9th 2024Three posters from the American Urological Association (AUA) 2024 Annual Meeting focused on urinary incontinence in female athletes, prenatal care for fetuses with spina bifida in California, and the experiences of women residents at the Brady Urological Institute.
Read More